Send to

Choose Destination
Urol Clin North Am. 2003 Aug;30(3):623-31.

Monoclonal antibody-based therapy for renal cell carcinoma.

Author information

Nijmegen Center for Molecular Life Sciences, 190 Experimental Urology, University Medical Center Nijmegen, Geert Grooteplein Zuid 28, 6525 Nijmegen, The Netherlands.


Monoclonal antibody G250 treatment may have a role in the management of metastatic RCC; however, particular subgroups who are more prone to benefit from this treatment must be delineated. High-risk patients may benefit from adjuvant treatment with this nontoxic treatment modality. Large cohort studies are needed to investigate this possibility.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center